Table 2 Studies which report lung function after statin treatment
Study | Study type | Group | Sample (Trial/Control) | Duration of treatment | Results (statin group compared with the control group) |
|---|---|---|---|---|---|
Ostroukhova et al., [18] | Retrospective study | Statin exposed vs statin unexposed | 50(24/26) | 2 years | 3% to 5% median worsening of FEV1 ↓ |
Braganza et al., [16] | RCT | Atorvastatin(40mg/day) vs placebo | 71 | 4weeks | No significant difference |
Moskovljevicet al., [28] | Controlled clinical trial | Atorvastatin(10mg/day) vs placebo | 9 | 4 weeks | No significant difference |
Menzies et al., [21] | RCT | Simvastatin(20mg/day,40mg/day)vs placebo | 16 | 4 weeks | No significant difference |
Hothersall et al., [22] | RCT | Atorvastatin(40mg/day) vs placebo | 54 | 8 weeks | No significant difference |
Cowan et al., [25] | RCT | Simvastatin(40mg/day) vs placebo | 43 | 4 weeks | PEF, FEV1 (p<0.01) ↑ |
Pagovich et al., [26] | Retrospective study | Atorvastatin, simvastatin vs baseline | 70 | 4 weeks | PF (p<0.0001) ↑ |
Foumani et al., [19] | RCT | Atorvastatin(40mg/day) vs placebo | 67 | 8 weeks | No significant difference |
Fahimi et al., [23] | RCT | Atorvastatin(10mg/day) vs placebo | 17 | 4 weeks | No significant difference |
Feschenko et al., [14] | RCT | Atorvastatin+ICS+Salbutamol vs ICS+salbutamol | 31 | 4 weeks | Morning PEF, FEV1 ↑ |
Adams et al., [27] | Retrospective study | Statin exposed vs statin unexposed | 539 | Not mentioned | No significant difference |
Moini et al., [24] | RCT | Atorvastatin(40mg/day) vs placebo | 62 | 8 weeks | No significant difference |